NCTN Gynecologic Cancer Trials Portfolio (Open as of 11/15/2022)

Each far right box includes the NCTN protocol number with a hyperlink to the associated
ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Low grade serous NRG-GY019

Newly
diagnosed High grade serous or NRG-
Endometrioid, Stage III or IV GY027
All HG
Epithelial
SOC/EOC/Clear NRG-
Cell, and others w GY023
BRCA mutation
Platinum
Recurrent High grade serous
Ovarian resistant
or Endometrioid,
cancer NRG-
Any histology w
GY029
BRCA1/BRCA2
mutation
Low-standard risk AGCT1531
Germ cell
Intermediate and poor risk metastatic AGCT1532
Gynecologic

Chemo-naïve, HER2 Serous carcinoma or

NRG-GY026
Positive, Stage I-IV Carcinosarcoma
Uterine
cancer Stage III/IV or recurrent NRG-GY018
NRG-GY012
Recurrent Any histology
dMMR NRG-GY025
Unifocal T1, Metastatic sentinel lymph
Vulva cancer NRG-
Tumor diameter node: > 2mm, or more than 1
(scc) GY024
< 4cm SN with metastasis ≤ 2mm
Extrapulmonary small cell Newly diagnosed, Poorly
S2012
neuroendocrine cancers (Gyne origin) differentiated, Metastatic
Trophoblastic tumors Recurrent S1609 (DART)
NCTN Gynecologic Cancer Trials Portfolio (Open as of 11/15/2022)
Each box below includes the NCTN protocol number with a hyperlink to the associated
ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

EAY131 (MATCH) S1609 (DART)

 NCTN Gynecologic Cancer  Trials (Open as of 11/15/2022)
Protocol Number Phase Protocol Title
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. 
AGCT1531 III Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with 
AGCT1532 III Intermediate and Poor‐Risk Germ Cell Tumors
A Randomized Phase II Study Comparing Single‐Agent Olaparib, Single Agent Cediranib, and the 
Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic 
NRG‐GY012 II Endometrial Cancer
A Phase III Randomized, Placebo‐Controlled Study of Pembrolizumab (MK‐3475, NSC #776864) in 
Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent 
NRG‐GY018 III Endometrial Cancer
A Randomized Phase III, Two‐Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus 
Letrozole Monotherapy in Patients with Stage II‐IV, Primary Low‐Grade Serous Carcinoma of the 
NRG‐GY019 III Ovary or Peritoneum
A Randomized Phase II Trial of Triplet Therapy (A PD‐L1 Inhibitor Durvalumab (MEDI4736) in 
Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab 
(MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum‐Resistant 
Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received 
NRG‐GY023 II Prior Bevacizumab
Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS‐V) III: A Prospective 
NRG‐GY024 II Phase II Treatment Trial

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy 
NRG‐GY025 II in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and 
Hyaluronidase‐oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase‐zzxf 
NRG‐GY026 II/III (PHESGO) in HER2 Positive, Stage I‐IV Endometrial Serous Carcinoma or Carcinosarcoma
Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin 
NRG‐GY027 I with Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80‐
6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients with 
Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have 
NRG‐GY029 II Progressed Through Prior PARP Inhibitor Therapy
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab 
(NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine 
S2012 II/III Carcinomas (NEC)
S1609 II DART: Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors
EAY131 II Molecular Analysis for Therapy Choice (MATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/